Article info
Research ethics
Paper
The nature and ethics of natural experiments
- Correspondence to Professor Julius Sim, Arthritis Research UK Primary Care Centre, Institute for Primary Care and Health Sciences, Keele University, Staffordshire ST5 5BG, UK; j.sim{at}keele.ac.uk
Citation
The nature and ethics of natural experiments
Publication history
- Received May 24, 2014
- Revised April 17, 2015
- Accepted June 16, 2015
- First published July 17, 2015.
Online issue publication
September 24, 2015
Article Versions
- Previous version (17 July 2015).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Other content recommended for you
- Health incentive research and social justice: does the risk of long term harms to systematically disadvantaged groups bear consideration?
- Forever young? The ethics of ongoing puberty suppression for non-binary adults
- Challenge studies of human volunteers: ethical issues
- Public health use of HIV phylogenetic data in sub-Saharan Africa: ethical issues
- Informed consent in cluster randomised trials: new and common ethical challenges
- Using natural experiments to evaluate population health interventions: new Medical Research Council guidance
- Increasing trend in hospitalisation due to adverse drug reactions: can we stem the tide?
- ‘Dark logic’: theorising the harmful consequences of public health interventions
- Eliminating latent tuberculosis in low-burden settings: are the principal beneficiaries to be disadvantaged groups or the broader population?
- The potential benefit of the placebo effect in sham-controlled trials: implications for risk-benefit assessments and informed consent